Early Endoscopic Indicators for OACs After Lung Transplantation: Development of a Novel Mucosal Healing Score

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Thomas Fuehner, Hannover Medical School
ClinicalTrials.gov Identifier:
NCT00940147
First received: July 14, 2009
Last updated: June 5, 2013
Last verified: June 2013
  Purpose

Airway complications are a significant cause of morbidity after lung transplantation (LTx). Bronchoscopic evaluation may help to identify risk factors for requiring interventions later.


Condition
Airway Complication Which Require Any Intervention

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Early Indicators for Obstructive Airway Complications After Lung

Resource links provided by NLM:


Further study details as provided by Hannover Medical School:

Primary Outcome Measures:
  • Primary endpoint of this study was any obstructive airway complication (AC) which required desobliterative intervention. [ Time Frame: 1 year ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • secondary endpoint included anastomosis-related death. [ Time Frame: 1 year ] [ Designated as safety issue: Yes ]

Enrollment: 180
Study Start Date: January 2007
Study Completion Date: August 2009
Primary Completion Date: June 2009 (Final data collection date for primary outcome measure)
Groups/Cohorts
1
patients with OAC, Score finding
2
patients without OAC, Score finding

Detailed Description:

The investigators evaluated lung transplant recipients prospectively. Adult patients surviving 90 day after LTx will be included. The investigators propose a classification of airway healing based on the endoscopic bronchial appearances at days 7, 14, 21, 90, 180 and 365 after LTx. A score system including mucosal healing, full tissue necrosis (=dehiscence), lose sutures, fibrin plugs, polyps and malacia will be developed (max. score 8 points/date). Endoscopic findings will be correlated with the development of obstructive airway complications (OAC, requiring >1 intervention). Afterwards the new score system will be applied prospectively in the patients.

  Eligibility

Ages Eligible for Study:   18 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

LTx 01.2007-05.2009

Criteria

Inclusion Criteria:

  • 3 month survivor after LTx
  • no OAC

Exclusion Criteria:

-

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00940147

Locations
Germany
Hannover Medical School
Hannover, Germany, 30625
Sponsors and Collaborators
Thomas Fuehner
  More Information

Additional Information:
No publications provided

Responsible Party: Thomas Fuehner, Principal Investigator, Hannover Medical School
ClinicalTrials.gov Identifier: NCT00940147     History of Changes
Other Study ID Numbers: 2008_01, OAC_1.0
Study First Received: July 14, 2009
Last Updated: June 5, 2013
Health Authority: Germany: Ethics Commission

ClinicalTrials.gov processed this record on August 19, 2014